Business Context and Reporting Period
This Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on October 26, 2017, reporting events occurring on October 27, 2016, and October 27, 2017. The company is a Delaware corporation focused on the dermatology market, having executed a turn-around strategy since 2014 to build a portfolio of prescription products and a direct sales force.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to specific compensatory arrangements:
- Director Stock Bonuses (2016): $100,000 per director awarded on October 27, 2016, for services related to the company turn-around.
- Director Stock Bonus (2017): $50,000 awarded to Director Jay Birnbaum on October 27, 2017, for 10 years of service.
- Grant Date: All awards are scheduled to be granted on January 2, 2018.
- Tax Gross-Up: The awards include a 40% tax gross-up to be paid in cash.
Material Changes
The filing reports the approval of discretionary stock bonuses for the Board of Directors. This represents a change in compensatory arrangements rather than a change in operational financial performance. The company notes that since 2014, it has grown from a zero baseline to selling nine prescription dermatology products in the United States with a sales team of 35 professionals.
Guidance, Outlook, and Management Commentary
Management commentary highlights the Board's active role in guiding the company's growth and exceeding expectations for commitment and expertise. The company maintains a strong product pipeline and a foundation in the dermatology market. No specific financial guidance, risk factors, or contingencies are detailed in this specific filing.
Key Facts for Investor Verification
- Verify the total cash impact of the 40% tax gross-up on the $100,000 and $50,000 stock awards.
- Confirm the exact number of shares to be issued on January 2, 2018, based on the stock price at that time.
- Review the company's most recent 10-K or 10-Q for actual revenue and cash flow figures, as this 8-K does not contain them.
- Assess the dilution impact of these awards on existing shareholders.